MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 318578 | Name: Progabide
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Progabide is an analog and prodrug of gamma-aminobutyric acid. It is commonly used in the treatment of epilepsy. Progabide has been investigated for many diseases besides epilepsy, including Parkinson's disease, schizophrenia, clinical depression and anxiety disorder with varying success.

Chemical Structure

Progabide
Progabide
CAS#62666-20-0

Theoretical Analysis

MedKoo Cat#: 318578

Name: Progabide

CAS#: 62666-20-0

Chemical Formula: C17H16ClFN2O2

Exact Mass: 334.0884

Molecular Weight: 334.77

Elemental Analysis: C, 60.99; H, 4.82; Cl, 10.59; F, 5.68; N, 8.37; O, 9.56

Price and Availability

Size Price Availability Quantity
5mg USD 350.00 2 Weeks
10mg USD 550.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Progabide; Halogabide; Gabrene; Gabren; Progabida; Progabidum; progabide; SL 76002; DB00837; LS-45438;
IUPAC/Chemical Name
4-[[(E)-(4-chlorophenyl)-(3-fluoro-6-oxocyclohexa-2,4-dien-1-ylidene)methyl]amino]butanamide
InChi Key
DWEQWXSKOHHBNT-VKAVYKQESA-N
InChi Code
InChI=1S/C17H16ClFN2O2/c18-12-5-3-11(4-6-12)17(21-9-1-2-16(20)23)14-10-13(19)7-8-15(14)22/h3-8,10,21H,1-2,9H2,(H2,20,23)/b17-14-
SMILES Code
C1=CC(=CC=C1C(=C2C=C(C=CC2=O)F)NCCCC(=O)N)Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Progabide has agonistic activity for both the GABAA and GABAB receptors.
In vitro activity:
Progabide and other antiepileptic drugs were examined for their effects on corticosterone-induced gene transcription chloramphenicol acetyltransferase activity in mouse fibroblast cells. Progabide, alongside felbamate and loreclezole, inhibited glucocorticoid receptor-mediated transcription, potentially impacting antiepileptic drug efficacy and immune system function. Reference: Pharmacol Rep. 2007 Sep-Oct;59(5):531-7. https://pubmed.ncbi.nlm.nih.gov/18048953/
In vivo activity:
This study investigated the effects of progabide on motor seizures induced by pentylenetetrazol in rats. The response to progabide varied with age: in adult rats, there was a tendency to suppress generalized tonic-clonic seizures, while in rat pups aged 7 to 18 days, progabide specifically suppressed the tonic phase of seizures. At 25 days of age, the only effect observed was an increase in the latency of major seizures at the highest progabide dose. Reference: Physiol Res. 1997;46(1):47-52. https://pubmed.ncbi.nlm.nih.gov/9728521/
Solvent mg/mL mM
Solubility
DMSO 250.0 746.78
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 334.77 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Basta-Kaim A, Budziszewska B, Leśkiewicz M, Regulska M, Otczyk M, Kubera M, Jagła G, Nowak W, Luszczki JJ, Czuczwar SJ, Lasoń W. Effects of some new antiepileptic drugs and progabide on glucocorticoid receptor-mediated gene transcription in LMCAT cells. Pharmacol Rep. 2007 Sep-Oct;59(5):531-7. PMID: 18048953. 2. Kroetz DL, Loiseau P, Guyot M, Levy RH. In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide. Clin Pharmacol Ther. 1993 Nov;54(5):485-97. doi: 10.1038/clpt.1993.180. PMID: 8222491. 3. Stanková L, Kozuchová A, Mares P. Anticonvulsant effect of progabide in rats during ontogenesis. Physiol Res. 1997;46(1):47-52. PMID: 9728521. 4. Kaneda H, Shirakawa O, Dale J, Goodman L, Bachus SE, Tamminga CA. Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats. Eur J Pharmacol. 1992 Feb 25;212(1):43-9. doi: 10.1016/0014-2999(92)90070-k. PMID: 1555638.
In vitro protocol:
1. Basta-Kaim A, Budziszewska B, Leśkiewicz M, Regulska M, Otczyk M, Kubera M, Jagła G, Nowak W, Luszczki JJ, Czuczwar SJ, Lasoń W. Effects of some new antiepileptic drugs and progabide on glucocorticoid receptor-mediated gene transcription in LMCAT cells. Pharmacol Rep. 2007 Sep-Oct;59(5):531-7. PMID: 18048953. 2. Kroetz DL, Loiseau P, Guyot M, Levy RH. In vivo and in vitro correlation of microsomal epoxide hydrolase inhibition by progabide. Clin Pharmacol Ther. 1993 Nov;54(5):485-97. doi: 10.1038/clpt.1993.180. PMID: 8222491.
In vivo protocol:
1. Stanková L, Kozuchová A, Mares P. Anticonvulsant effect of progabide in rats during ontogenesis. Physiol Res. 1997;46(1):47-52. PMID: 9728521. 2. Kaneda H, Shirakawa O, Dale J, Goodman L, Bachus SE, Tamminga CA. Co-administration of progabide inhibits haloperidol-induced oral dyskinesias in rats. Eur J Pharmacol. 1992 Feb 25;212(1):43-9. doi: 10.1016/0014-2999(92)90070-k. PMID: 1555638.
1: Tak H, Anirudh J, Chattopadhyay A, Naick BH. Argonaute protein assisted drug discovery for miRNA-181c-5p and target gene ATM translation repression: a computational approach. Mol Divers. 2024 Jul 18. doi: 10.1007/s11030-024-10855-3. Epub ahead of print. PMID: 39026118. 2: Ataollahi E, Solhjoo A, Rezaei Z, Behrouz M, Heidari R, Shahbazi MR, Foroozanad R, Zamani L, Khabnadideh S, Emami L. Novel 1,4 benzothiazine 3-one derivatives as anticonvulsant agents: Design, synthesis, biological evaluation and computational studies. Comput Biol Chem. 2023 Jun;104:107870. doi: 10.1016/j.compbiolchem.2023.107870. Epub 2023 Apr 14. PMID: 37099900. 3: Kale A, Kakde R, Pawar S, Jagtap V, Dorugade R. Importance of Pharmacophore in Designing Anticonvulsant Agents. CNS Neurol Disord Drug Targets. 2023;22(4):500-511. doi: 10.2174/1871527321666220401115529. PMID: 35366788. 4: Pal R, Singh K, Paul J, Khan SA, Naim MJ, Akhtar MJ. Overview of Chemistry and Therapeutic Potential of Non-Nitrogen Heterocyclics as Anticonvulsant Agents. Curr Neuropharmacol. 2022;20(8):1519-1553. doi: 10.2174/1570159X19666210803144815. PMID: 34344289; PMCID: PMC9881093. 5: Bellofatto M, De Michele G, Iovino A, Filla A, Santorelli FM. Management of Hereditary Spastic Paraplegia: A Systematic Review of the Literature. Front Neurol. 2019 Jan 22;10:3. doi: 10.3389/fneur.2019.00003. PMID: 30723448; PMCID: PMC6349696. 6: Alabed S, Latifeh Y, Mohammad HA, Bergman H. Gamma-aminobutyric acid agonists for antipsychotic-induced tardive dyskinesia. Cochrane Database Syst Rev. 2018 Apr 17;4(4):CD000203. doi: 10.1002/14651858.CD000203.pub4. PMID: 29663328; PMCID: PMC6513215. 7: Fijałkowski Ł, Sałat K, Podkowa A, Zaręba P, Nowaczyk A. Potential role of selected antiepileptics used in neuropathic pain as human GABA transporter isoform 1 (GAT1) inhibitors-Molecular docking and pharmacodynamic studies. Eur J Pharm Sci. 2017 Jan 1;96:362-372. doi: 10.1016/j.ejps.2016.10.004. Epub 2016 Oct 6. PMID: 27721044. 8: Li XQ, Hayes MA, Grönberg G, Berggren K, Castagnoli N Jr, Weidolf L. Discovery of a Novel Microsomal Epoxide Hydrolase-Catalyzed Hydration of a Spiro Oxetane. Drug Metab Dispos. 2016 Aug;44(8):1341-8. doi: 10.1124/dmd.116.071142. Epub 2016 Jun 2. PMID: 27256986. 9: Rosa M, Bonnaillie P, Chanteux H. Prediction of drug-drug interactions with carbamazepine-10,11-epoxide using a new in vitro assay for epoxide hydrolase inhibition. Xenobiotica. 2016 Dec;46(12):1076-1084. doi: 10.3109/00498254.2016.1151088. Epub 2016 Mar 3. PMID: 26936324. 10: Wang M, Kong L, Li Z, Zhang L. Covariance estimators for generalized estimating equations (GEE) in longitudinal analysis with small samples. Stat Med. 2016 May 10;35(10):1706-21. doi: 10.1002/sim.6817. Epub 2015 Nov 19. PMID: 26585756; PMCID: PMC4826860. 11: Gargiulo R, Suhail F, Lerma EV. Cardiovascular disease and chronic kidney disease. Dis Mon. 2015 Sep;61(9):403-13. doi: 10.1016/j.disamonth.2015.07.005. Epub 2015 Aug 29. PMID: 26328516. 12: Miyoshi H, Oishi Y, Mizuguchi Y, Iuchi A, Nagase N, Ara N, Oki T. Association of left atrial reservoir function with left atrial structural remodeling related to left ventricular dysfunction in asymptomatic patients with hypertension: evaluation by two-dimensional speckle-tracking echocardiography. Clin Exp Hypertens. 2015;37(2):155-65. doi: 10.3109/10641963.2014.933962. Epub 2014 Jul 22. PMID: 25050647. 13: Rejdak K, Nieoczym D, Czuczwar M, Kiś J, Wlaź P, Turski WA. Orphenadrine- induced convulsive status epilepticus in rats responds to the NMDA antagonist dizocilpine. Pharmacol Rep. 2014 Jun;66(3):399-403. doi: 10.1016/j.pharep.2013.12.007. Epub 2014 Apr 2. PMID: 24905515. 14: Zhang DK, Chen M, Liu Y, Wang RF, Liu LP, Li M. Acoustic radiation force impulse elastography for non-invasive assessment of disease stage in patients with primary biliary cirrhosis: A preliminary study. Clin Radiol. 2014 Aug;69(8):836-40. doi: 10.1016/j.crad.2014.03.019. Epub 2014 May 16. PMID: 24837697. 15: Moreno E, Vázquez-Polo FJ, Negrín MA. Objective Bayesian meta-analysis for sparse discrete data. Stat Med. 2014 Sep 20;33(21):3676-92. doi: 10.1002/sim.6163. Epub 2014 Apr 8. PMID: 24710961. 16: Westgate PM. A bias correction for covariance estimators to improve inference with generalized estimating equations that use an unstructured correlation matrix. Stat Med. 2013 Jul 20;32(16):2850-8. doi: 10.1002/sim.5709. Epub 2012 Dec 16. PMID: 23255154. 17: Nabbout R, Chiron C. Stiripentol: an example of antiepileptic drug development in childhood epilepsies. Eur J Paediatr Neurol. 2012 Sep;16 Suppl 1:S13-7. doi: 10.1016/j.ejpn.2012.04.009. Epub 2012 Jun 12. PMID: 22695038. 18: Carey VJ, Wang YG. Working covariance model selection for generalized estimating equations. Stat Med. 2011 Nov 20;30(26):3117-24. doi: 10.1002/sim.4300. Epub 2011 Jul 11. PMID: 21748775. 19: Schmidt D. Antiepileptic drug discovery: does mechanism of action matter? Epilepsy Behav. 2011 Aug;21(4):342-3. doi: 10.1016/j.yebeh.2011.03.037. Epub 2011 May 10. PMID: 21561810. 20: Hagino T, Ochiai S, Sato E, Watanabe Y, Senga S, Haro H. Prognostic prediction in patients with hip fracture: risk factors predicting difficulties with discharge to own home. J Orthop Traumatol. 2011 Jun;12(2):77-80. doi: 10.1007/s10195-011-0138-y. Epub 2011 May 4. PMID: 21541772; PMCID: PMC3102807.